letrozole has been researched along with Thrombopenia in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of palbociclib to endocrine therapy has been shown to improve progression free survival in hormone receptor positive metastatic breast cancer patients." | 9.12 | [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?] ( Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L, 2021) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 7.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease." | 5.72 | Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia. ( Annovazzi, A; Barberi, V; Cognetti, F; Ferretti, G; Renna, D; Russillo, M, 2022) |
| "The addition of palbociclib to endocrine therapy has been shown to improve progression free survival in hormone receptor positive metastatic breast cancer patients." | 5.12 | [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?] ( Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L, 2021) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 3.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease." | 1.72 | Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia. ( Annovazzi, A; Barberi, V; Cognetti, F; Ferretti, G; Renna, D; Russillo, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barberi, V | 1 |
| Renna, D | 1 |
| Annovazzi, A | 1 |
| Ferretti, G | 1 |
| Russillo, M | 1 |
| Cognetti, F | 1 |
| Ham, A | 1 |
| Kim, MH | 1 |
| Kim, GM | 1 |
| Kim, JH | 1 |
| Kim, JY | 1 |
| Park, HS | 1 |
| Park, S | 1 |
| Cho, YU | 1 |
| Park, BW | 1 |
| Kim, SI | 1 |
| Sohn, J | 1 |
| Vazquez, L | 1 |
| Arnaud, A | 1 |
| Grenier, J | 1 |
| Debourdeau, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients[NCT06076772] | 54 participants (Anticipated) | Observational [Patient Registry] | 2023-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for letrozole and Thrombopenia
| Article | Year |
|---|---|
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyc | 2021 |
2 other studies available for letrozole and Thrombopenia
| Article | Year |
|---|---|
Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Middle | 2022 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Li | 2020 |